Induced pluripotent stem cells from a spinal muscular atrophy patient
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Spinal muscular atrophy is one of the most common inherited forms of neurological disease leading to infant mortality. Patients have selective loss of lower motor neurons resulting in muscle weakness, paralysis and often death. Although patient fibroblasts have been used extensively to study spinal muscular atrophy, motor neurons have a unique anatomy and physiology which may underlie their vulnerability to the disease process. Here we report the generation of induced pluripotent stem cells from skin fibroblast samples taken from a child with spinal muscular atrophy. These cells expanded robustly in culture, maintained the disease genotype and generated motor neurons that showed selective deficits compared to those derived from the child's unaffected mother. This is the first study to show that human induced pluripotent stem cells can be used to model the specific pathology seen in a genetically inherited disease. As such, it represents a promising resource to study disease mechanisms, screen new drug compounds and develop new therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SMA iPSC-derived motor neurons showed a higher vulnerability with reduced dendritic and axonal length.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Technologies to reprogram adult cells back to a pluripotent state, termed induced pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006; Yu et al., 2007), provide an unprecedented platform for studying human genetic disorders (Ebert et al., 2009; Mattis et al., 2015).”
From Modeling Psychomotor Retardation using iPSCs from MCT8-Deficient Patients Indicates a Prominent Role for the Blood-Brain Barrier (2017) · cites this paper as Ebert et al., 2009
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“RNA analysis from SMA iPSC-derived motor neuron demonstrates hyperactivation of the endoplasmic reticulum (ER) stress pathway due to activated unfolded SMN [49].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [49]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Self-citationBolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,266
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
CNS stem cells express a new class of intermediate filament protein
Lendahl, U., Zimmerman, L. B., & McKay, R. D. G. (1990) · Cell · doi:10.1016/0092-8674(90)90662-x · Cited by 3,151
Pvclust: an R package for assessing the uncertainty in hierarchical clustering
Suzuki, R., & Shimodaira, H. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl117 · Cited by 2,451
Reprogramming of human somatic cells to pluripotency with defined factors
Park, I.-H., Zhao, R., West, J. A., Yabuuchi, A., Huo, H., Ince, T. A., Lerou, P. H., Lensch, M. W., & Daley, G. Q. (2008) · Nature · doi:10.1038/nature06534 · Cited by 2,436
Disease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196
Neuronal specification in the spinal cord: inductive signals and transcriptional codes
Jessell, T. M. (2000) · Nature Reviews Genetics · doi:10.1038/35049541 · Cited by 2,089
Cited by
Items 901–1,000 of 1,000
Firas, J., Liu, X., Nefzger, C. M., & Polo, J. M. (2014) · Differentiation · doi:10.1016/j.diff.2014.05.003 · Cited by 10
Induced pluripotent stem (iPS) cells: an up-to-the-minute review
Lau, F. H., Ahfeldt, T., Osafune, K., Akustsu, H., & Cowan, C. A. (2009) · F1000 Biology Reports · doi:10.3410/b1-84 · Cited by 12
“Groups led by Svendsen [20] and Jaenisch [21] have added to the list of disease-specific iPS cells by creating human cell-based models of spinal muscular atrophy and Parkinson’s disease, respectively.”
BackgroundPluripotent stem cell for modeling neurological diseases
Yung, J. S.-Y., Tam, P. K. H., & Ngan, E. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.11.007 · Cited by 12
Dedifferentiation rescues senescence of progeria cells but only while pluripotent
Niedernhofer, L. J., Glorioso, J. C., & Robbins, P. D. (2011) · Stem Cell Research & Therapy · doi:10.1186/scrt69 · Cited by 10
“For example, motor neurons diff erentiated from iPSCs produced from patients with spinal muscular atrophy are smaller, have impaired pre-synaptic maturation, and degenerate more rapidly than motor neurons produced from normal iPSCs [8].”
BackgroundYang, D., Zhu, L., Ren, J., Ma, R., Zhu, H., & Xu, J. (2015) · Neuroscience Bulletin · doi:10.1007/s12264-015-1541-9 · Cited by 12
Tu, J., Cao, D., Li, L., Cheung, H., & Chan, W. (2018) · FEBS Open Bio · doi:10.1002/2211-5463.12377 · Cited by 11
Research on neurodegenerative diseases using induced pluripotent stem cells
Imamura, K., & Inoue, H. (2012) · Psychogeriatrics · doi:10.1111/j.1479-8301.2011.00394.x · Cited by 11
Advances and challenges in developing a therapy for spinal muscular atrophy
Anderton, R. S., & Mastaglia, F. L. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1059757 · Cited by 13
“Further, recent generation of induced pluripotent stem cell-based SMA models [86] has significantly improved the validity of in vitro modeling, allowing a more comprehensive assessment of neuronal physiology following treatment.”
Isolation and in vitro propagation of human skeletal muscle progenitor cells from fetal muscle
Hosoyama, T., Meyer, M. G., Krakora, D., & Suzuki, M. (2013) · Cell Biology International · doi:10.1002/cbin.10026 · Cited by 10
“, 1998) and human pluripotent stem cells (Ebert et al., 2009).”
BackgroundMethodUpdate on gene and stem cell therapy approaches for spinal muscular atrophy
Donnelly, E. M., & Boulis, N. M. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.711306 · Cited by 13
“iPS cells derived from SMA patients can be differentiated into motor neurons for further study of the disease pathology [58].”
BackgroundiPSC for Dental Tissue Regeneration
Hynes, K., Gronthos, S., & Bartold, P. M. (2014) · Current Oral Health Reports · doi:10.1007/s40496-013-0001-8 · Cited by 10
Stem cells as a resource for regenerative neurology
Connick, P., Patani, R., & Chandran, S. (2011) · Practical Neurology · doi:10.1136/jnnp.2010.235184 · Cited by 10
Fu, S., Ding, J.-W., Liu, D., Huang, H., Li, M., Liu, Y., Tu, L., & Liu, D. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3206 · Cited by 11
Targeting Purinergic Signaling and Cell Therapy in Cardiovascular and Neurodegenerative Diseases
Andrejew, R., Glaser, T., Oliveira‐Giacomelli, Á., Ribeiro, D. E., de Godoy, M. A., Granato, A. E. C., & Ulrich, H. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-31206-0_14 · Cited by 10
Nuclear reprogramming and induced pluripotent stem cells: a review for surgeons
Qi, S. D., Smith, P. D., & Choong, P. (2012) · ANZ Journal of Surgery · doi:10.1111/j.1445-2197.2012.06282.x · Cited by 9
DNA methylation profiles provide a viable index for porcine pluripotent stem cells
Arai, Y., Ohgane, J., Fujishiro, S., Nakano, K., Matsunari, H., Watanabe, M., Umeyama, K., Azuma, D., Uchida, N., Sakamoto, N., et al. (2013) · genesis · doi:10.1002/dvg.22423 · Cited by 9
“Therefore, the generation and evaluation of porcine iPSCs will provide useful information that could help promote clinical application of human iPSCs (Ezashi et al., 2009; Fujishiro et al., 2013; Montserrat et al., 2011; West et al., 2010; Wu et al., 2009).”
BackgroundPatient-derived cellular models of primary ciliopathies
Pollara, L., Sottile, V., & Valente, E. M. (2022) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2021-108315 · Cited by 11
Cao, Y., Li, L., Ren, X., Mao, B., Yang, Y., Mi, H., Guan, Y., Li, S., Zhou, S., Guan, X., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4783 · Cited by 14
“Recently, much effort has focused on advancing induced pluripotent stem cell (iPSC) therapies and gene reprogramming techniques, which enable the generation of patient-specific iPSCs from somatic cells.((22,23)) Because iPSCs express pluripotency genes such asOCT4, SOX2, and SSEA1,((24)) they can differentiate into a…”
BackgroundSierra-Delgado, J. A., Ray, S. S., Kaleem, A., Ganjibakhsh, M., Parvate, M., Powers, S., Zhang, X., Likhite, S. B., & Meyer, K. (2023) · Biology · doi:10.3390/biology12060867 · Cited by 10
“It is noteworthy that earlier research utilizing iPSC lines from SMA patients showed a decreased capacity for neuronal differentiation that could be improved upon restoration of SMN expression [23,32,33].”
BackgroundResultA longevity‐specific bank of induced pluripotent stem cells from centenarians and their offspring
Dowrey, T. W., Cranston, S. F., Skvir, N. J., Lok, Y., Gould, B., Petrowitz, B., Villar, D., Shan, J., James, M. F., Dodge, M., et al. (2024) · Aging Cell · doi:10.1111/acel.14351 · Cited by 13
“…discovery, iPSCs have been used to model diseases as well as screen drugs for the treatment of amyotrophic lateral sclerosis (Egawa et al., 2012 ), spinal muscular atrophy (Ebert et al., 2009), and other neurodegenerative (Okano & Morimoto, 2022 ) and muscular (Rashid et al., 2023 ) disorders.”
The Relevance of Spinal Muscular Atrophy Biomarkers in the Treatment Era
Maretina, M. A., Koroleva, V., Shchugareva, L. M., Glotov, A. S., & Kiselev, A. (2024) · Biomedicines · doi:10.3390/biomedicines12112486 · Cited by 10
Cell and tissue reprogramming: Unlocking a new era in medical drug discovery
Sen, C. K., Friday, A. J., & Roy, S. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100077 · Cited by 11
Co-regulation of pluripotency and genetic integrity at the genomic level
Cooper, D. J., Walter, C. A., & McCarrey, J. R. (2014) · Stem Cell Research · doi:10.1016/j.scr.2014.09.006 · Cited by 10
“Human transcriptome datasets with biological replicates used in this study were those from GSE25970 (Bock et al., 2011), the super series of GSE26451 and GSE26453 (Munoz et al., 2011), GSE13828 (Ebert et al., 2008), GSE9865 (Lowry et al., 2008), GSE12390 (Maherali et al., 2008), GSE14982 (Sun et al., 2009), and GSE151…”
MethodGreat Expectations: Induced pluripotent stem cell technologies in neurodevelopmental impairments
Zhang, X., Li, Z., Liu, Y., & Gai, Z. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.51842 · Cited by 10
“Since then, many researchers have also adopted the same method to obtain iPSCs [4-9].”
MethodOrr, M. E., Pitstick, R., Canine, B., Ashe, K. H., & Carlson, G. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039328 · Cited by 12
Biobanking in the Era of the Stem Cell: A Technical and Operational Guide
Moore, J. C., Sheldon, M., & Hart, R. P. (2012) · Colloquium Series on Stem Cell Biology · doi:10.4199/c00059ed1v01y201206scb002 · Cited by 10
Cherkashova, E. A., Leonov, G. E., Namestnikova, D. D., Соловьева, А. А., Gubskiy, I. L., Bukharova, T. B., Губский, Л. В., Goldstein, D. V., & Yarygin, K. N. (2020) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-020-04754-4 · Cited by 10
“IPSC are now used for modeling various pathologies, including mucopolysaccharidosis [28], vitiligo [34], Brugada syndrome [50], amyloidosis [31], schizophrenia [58], bipolar disorder [44], as well as neurological diseases such as multiple sclerosis, spinal muscular atrophy [16], amyotrophic lateral sclerosis, and Alzh…”
Induced pluripotent stem cells and neurological disease models.
Cai, S., Chan, Y.-S., & Shum, D. K.-Y. (2014) · PubMed · doi:10.13294/j.aps.2014.0008 · Cited by 9
Neural Stem/Progenitor Cells for Spinal Cord Regeneration
Salewski, R. P., Emrani, H., & Michael, G. (2013) · InTech eBooks · doi:10.5772/55054 · Cited by 12
Bigley, T. M., McGivern, J. V., Ebert, A. D., & Terhune, S. S. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.02.007 · Cited by 9
“These results indicate that EZ-sphere-derived NPCs are predominantly undifferentiated and are susceptible to HCMV infection.”
ResultSelf-citationJendelová, P., Syková, E., & Erceg, S. (2018) · Results and problems in cell differentiation · doi:10.1007/978-3-319-93485-3_3 · Cited by 9
An Overview of Pluripotent Stem Cells
Bhartiya, D., Nagvenkar, P. V., Sriraman, K., & Shaikh, A. (2013) · InTech eBooks · doi:10.5772/55130 · Cited by 13
Advances in iPSC Technology in Neural Disease Modeling, Drug Screening, and Therapy
Dai, S., Qiu, L., Veeraraghavan, V. P., Sheu, C., & Mony, U. (2023) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x18666230608105703 · Cited by 9
iPSC-Based Models to Unravel Key Pathogenetic Processes Underlying Motor Neuron Disease Development
Faravelli, I., Frattini, E., Ramirez, A., Stuppia, G., Nizzardo, M., & Corti, S. P. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3041124 · Cited by 10
“Ebert and Svendsen were the first authors to demonstrate that human iPSCs can be employed to recapitulate the specific pathology that underlies SMA [48].”
BackgroundMethodHuman-Derived Neurons and Neural Progenitor Cells in High Content Imaging Applications
Harrill, J. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7357-6_18 · Cited by 10
Liang, K. X., Kristiansen, C. K., Vatne, G. H., Hong, Y., & Bindoff, L. A. (2020) · Cell and Tissue Research · doi:10.1007/s00441-019-03164-x · Cited by 8
“2012) and spinal muscular atrophy (SMA) type I (Ebert et al. 2009).”
BackgroundWong, G., & Chiu, A. T. (2010) · Biotechnology Advances · doi:10.1016/j.biotechadv.2010.05.019 · Cited by 11
Brown, S. J., Kline, R. A., Synowsky, S. A., Shirran, S. L., Holt, I., Sillence, K. A., Claus, P., Wirth, B., Wishart, T. M., & Fuller, H. R. (2022) · Cells · doi:10.3390/cells11172624 · Cited by 8
“A study in which SMA fibroblasts were used to generate induced pluripotent stem (iPS) cells that were subsequently used to generate motor neurons enabled specific analysis of motor neurons affected by SMA [64].”
BackgroundA self‐deletion lentiviral vector to reduce the risk of replication‐competent virus formation
Fang, Y., Gong, X., Xu, M., Zeng, F., & Zhang, J. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2700 · Cited by 8
“The success of generating transgenic mice with our self-deletion particle indicated that it did not lose much titer by our approach and the self-deletion process functioned well in vivo, although the transgenic efficiency could be lower than the conventional viral transgenic mean (Figure 4; see also Supporting informa…”
BackgroundViollet, L., & Melki, J. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-444-59565-2.00010-1 · Cited by 8
Kim, J. S., Choi, H. W., Choi, S., Seo, H. G., Moon, S., Chung, H., & Tae, J. (2014) · Stem Cells and Development · doi:10.1089/scd.2014.0020 · Cited by 9
Generation of Induced Pluripotent Stem Cells from Dental Pulp Somatic Cells
Nelson, F., Kerkis, I., & Wenceslau, C. V. (2013) · InTech eBooks · doi:10.5772/55856 · Cited by 9
“…cell types affected by the disease, such as, spinal motor neurons, dopaminergic neurons and cardiomyocytes derived from patients suffering from amyotrophic lateral sclerosis (Dimos et al., 2008), spinal muscular atrophy (Ebert et al., 2009), sporadic Parkinson’s disease (Soldner et al., 2009).”
BackgroundCellular models for disease exploring and drug screening
Li, Z., & Zhou, Q. (2010) · Protein & Cell · doi:10.1007/s13238-010-0027-9 · Cited by 9
“The SMN1 gene in these motor neurons is less expressed, and the formation of synapse is delayed (Ebert et al., 2009).”
BackgroundSzebényi, K., Erdei, Z., Péntek, A., Sebe, A., Orbán, T. I., Sarkadi, B., & Apáti, Á. (2011) · Personalized Medicine · doi:10.2217/pme.11.19 · Cited by 13
Establishment of Tsc2-deficient rat embryonic stem cells
ITO, Y., Kawano, H., Kanai, F., Nakamura, E., Tada, N., Takai, S., Horie, S., Arai, H., Kobayashi, T., & Hino, O. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2913 · Cited by 8
Amyotrophic lateral sclerosis: applications of stem cells – an update
Cova, L., & Silani, V. (2010) · Stem Cells and Cloning Advances and Applications · doi:10.2147/sccaa.s8662 · Cited by 12
Embryonic and Induced Pluripotent Stem Cells as a Model for Liver Disease
Yagi, H., Tafaleng, E. N., Nagaya, M., Hansel, M. C., Strom, S. C., Fox, I. J., & Soto–Gutiérrez, A. (2009) · Critical Reviews in Biomedical Engineering · doi:10.1615/critrevbiomedeng.v37.i4-5.40 · Cited by 8
Human Pluripotent Stem Cells for Genetic Disease Modeling and Drug Screening
Gauthier, M., Maury, Y., Peschanski, M., & Martinat, C. (2011) · Regenerative Medicine · doi:10.2217/rme.11.46 · Cited by 11
New iPSC for old long QT syndrome modeling: Putting the evidence into perspective
Li, G., Cheng, G., Wu, J., Ma, S., & Sun, C. (2013) · Experimental Biology and Medicine · doi:10.1177/1535370213514000 · Cited by 8
“Several therapeutic relevant cell types derived from iPSCs have been tested to treat diseases in animal models.(28,82) Mouse iPSCs can be used for the restoration of physiological function of diseased tissues in vivo, as demonstrated by using iPSC-derived hematopoietic cells in a humanized mouse model of sickle cell a…”
BackgroundRegulation of Neural Stem Cell Fate by Natural Products
Kim, H. (2018) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2018.184 · Cited by 8
Cifelli, J. L., Berg, K. R., & Yang, J. (2020) · FEBS Open Bio · doi:10.1002/2211-5463.12788 · Cited by 9
Defining Stem Cells? Scientists and Their Classifications of Nature
Marks, N. J. (2010) · The Sociological Review · doi:10.1111/j.1467-954x.2010.01910.x · Cited by 9
“However, a new but similar challenge has risen against ESCR in the form of ‘induced pluripotent stem cells’ which come from adult tissues and can relatively easily be given a similar differentiation potential to ES cells under laboratory conditions (Aoi et al., 2008; Ebert et al., 2009).”
BackgroundThe Art of Human Induced Pluripotent Stem Cells: The Past, the Present and the Future
Zhang, X., Angeles, A. D. L., & Zhang, J. (2010) · The Open Stem Cell Journal · doi:10.2174/1876893801002010002 · Cited by 11
Zeng, S., Yang, H., Wang, B., Xie, Y., Xu, K., Liu, L., Cao, W., Liu, X., Tang, B., Liu, M., et al. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.375347 · Cited by 8
“In accordance with a previously reported protocol (Ebert et al., 2009), primary epithelial cells were subjected to reprogramming by co-transfection with an oriP/EBNA1-based episomal vector, pCEP4-O2SET2K (Plasmid# 20927, Addgene, Watertown, MA, USA), which carries OCT4, SOX2, KLF4, and SV40LT,…”
May, A., Ventura, T., Fidanza, A., Volmer, H., Taylor, H., Romanò, N., D’Souza, S. L., Bieker, J. J., & Forrester, L. M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1148013 · Cited by 7
“iPSCs have been successfully used to model a variety of diseases and disease-specific pathologies, including Spinal Muscular Atrophy, Long-QT syndrome, and Brugada Syndrome (Ebert et al., 2009; Moretti et al., 2010; Liang et al., 2016; El-Battrawy et al., 2018; El-Battrawy et al., 2021).”
MethodEffect of Honokiol on culture time and survival of Alzheimer’s disease iPSC-derived neurons
Le, D. T. T., Vu, C. M., Ly, T. T. B., Nguyen, N., Nguyen, P. T. M., & Hà, C. H. (2023) · Bioimpacts · doi:10.34172/bi.2023.27652 · Cited by 8
Primary immunodeficiency modeling with induced pluripotent stem cells
Pessach, I. M., & Notarangelo, L. D. (2011) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e32834cb943 · Cited by 7
iPS and ES Cells: Do Both Roads Lead to Rome?
Ng, V. Y., & Choo, A. B. H. (2010) · The Open Stem Cell Journal · doi:10.2174/1876893801002010008 · Cited by 7
“Indeed, the SMA-iPS cells demonstrated the expected increase in survivin motor neuron 1 after treatment with valproic acid and tobramycin [31].”
BackgroundDeriving, regenerating, and engineering CNS tissues using human pluripotent stem cells
Lemke, K. A., Aghayee, A., & Ashton, R. S. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.05.010 · Cited by 9
Lito, S., Sidibé, A., Ilmjärv, S., Burda, P., Baumgartner, M. R., Wehrle‐Haller, B., Krause, K., & Marteyn, A. (2020) · Cells · doi:10.3390/cells9122593 · Cited by 7
Luo, Y., Fan, Y., Chen, X., Yu, B., Lei, Y. U. E., Wang, D., Li, Q., Chen, Y., & Sun, X. (2012) · Journal of Reproduction and Development · doi:10.1262/jrd.2012-059 · Cited by 7
Recapitulating Long-QT Syndrome Using Induced Pluripotent Stem Cell Technology
Dirschinger, R. J., Goedel, A., Moretti, A., Laugwitz, K., & Sinnecker, D. (2012) · Pediatric Cardiology · doi:10.1007/s00246-012-0286-8 · Cited by 7
“The first demonstrations of this emerging technology have been models of monogenetic neurodegenerative [7, 19] and”
BackgroundProspect of Induced Pluripotent Stem Cell Genetic Repair to Cure Genetic Diseases
Pawitan, J. A. (2012) · Stem Cells International · doi:10.1155/2012/498197 · Cited by 9
“To date, iPSCs for various genetic diseases have been developed, such as for certain type of Parkinson’s disease [5], spinal muscular atrophy [6], lentigines, electrocardiographic abnormalities, ocular hypertelorism, pulmonary valve steno-”
BackgroundBarbaric, I., Allison, T. F., Powles-Glover, N. S., Biga, V., & Andrews, P. W. (2015) · International Journal of High Throughput Screening · doi:10.2147/ijhts.s58113 · Cited by 9
“The first reported instance of the use of hiPSCs in disease modeling was in the case of spinal muscular atrophy.(68) Ebert et al were able to show that a mutation within the spinal muscular atrophy gene did not affect motor neuron specification; however, motor neuron production was hindered, and degeneration increased…”
Jung‐Klawitter, S., & Opladen, T. (2018) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-018-0225-9 · Cited by 9
Liras, A., Segovia, C., & Aline, S. (2013) · InTech eBooks · doi:10.5772/55816 · Cited by 8
Viable iPSC mice: a step closer to therapeutic applications in humans?
Betts, D. H., & Kalionis, B. (2009) · Molecular Human Reproduction · doi:10.1093/molehr/gap101 · Cited by 7
“In addition, numerous pluripotent stem cell lines have been generated from the cells of human patients with specific diseases (Dimos et al., 2008; Park et al., 2008a; Ebert et al., 2009; Lee et al., 2009; Maehr et al., 2009; Soldner et al., 2009; Ye et al., 2009).”
BackgroundReprogramming of adult human neural stem cells into induced pluripotent stem cells
Xie, L., Sun, H., Wang, T., Tang, H., Wang, P., Zhu, J., Yao, Z.-W., & Feng, X. (2013) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20122755 · Cited by 7
Generation of Human-Induced Pluripotent Stem Cells by Lentiviral Transduction
Moore, J. C. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-348-0_4 · Cited by 7
Pluripotent Stem Cells and Their Dynamic Niche
Reinwald, Y., Bratt, J. A. J., & Haj, A. J. E. (2016) · InTech eBooks · doi:10.5772/62671 · Cited by 10
“Spinal muscular atrophy Motor neurons hiPSC Loss of SMN gene expression and neuron formation, drug tested [310]”
BackgroundLuecke, I. W., Lin, G. H. Y., Santarriaga, S., Scaglione, K. M., & Ebert, A. D. (2021) · Gene Therapy · doi:10.1038/s41434-021-00276-4 · Cited by 7
Self-citationStem Cell Therapy for Neuromuscular Diseases
Meregalli, M., Farini, A., & Torrente, Y. (2011) · InTech eBooks · doi:10.5772/24013 · Cited by 12
“interest are iPS cells derived from neurodegenerative diseases (Dimos et al., 2008; Ebert et al., 2009).”
BackgroundLes cellules souches pluripotentes induites
Germain, D. (2009) · Pathologie Biologie · doi:10.1016/j.patbio.2009.09.017 · Cited by 9
Proteomic and functional comparison between human induced and embryonic stem cells
Brenes, A. J., Griesser, E., Sinclair, L. V., Davidson, L., Prescott, A. R., Singh, F., Hogg, E. K. J., Espejo-Serrano, C., Jiang, H., Yoshikawa, H., et al. (2024) · eLife · doi:10.7554/elife.92025.3 · Cited by 8
Induced pluripotent stem cell for modeling Pompe disease
Huang, W., Zhang, Y., & Zhou, R. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1061384 · Cited by 6
Cook, S. L., Stout, C., Kirkeby, L. A., Vidal‐Folch, N., Oglesbee, D., Hasadsri, L., Selcen, D., Milone, M., Anderson, D., & Staff, N. P. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1406819 · Cited by 6
Induced Pluripotent Stem Cells as Human Disease Models
Dimos, J. T., Griswold‐Prenner, I., Grs̆ković, M., Irion, S., Johnson, C., & Vaisberg, E. A. (2011) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-386009-5.00005-9 · Cited by 6
Experimental and Therapeutic Opportunities for Stem Cells in Multiple Sclerosis
Patani, R., & Chandran, S. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131114470 · Cited by 9
“To date, proof-of-concept studies using iPSCs have recapitulated the pathological phenotype of neurons from patients with inherited and sporadic developmental and adult brain disorders that include spinal muscular atrophy [117], familial dyautonomia [118], Rett syndrome [119], Parkinson’s disease [120] and Motor neuro…”
PLURIPOTENCY AND CELLULAR REPROGRAMMING
Moura, M. T. (2013) · Anais da Academia Pernambucana de Ciência Agronômica · Cited by 7
Nuclear reprogramming and induced pluripotent stem cells: a review for surgeons
Qi, S. D., Smith, P. D., & Choong, P. (2014) · ANZ Journal of Surgery · doi:10.1111/ans.12419 · Cited by 11
Al-Hilal, H., Maretina, M. A., Egorova, A., Glotov, A. S., & Kiselev, A. (2024) · Methods and Protocols · doi:10.3390/mps7010009 · Cited by 6
“Moreover, similar results were observed in iPS-SMA-derived neural cells after treatment with valproic acid and tobramycin [16].”
BackgroundResultValetdinova, K. R., Medvedev, S. P., & Zakian, S. M. (2015) · Acta Naturae · doi:10.32607/20758251-2015-7-1-19-36 · Cited by 7
STEM CELLS, SCIENCE, AND PUBLIC REASONING
Hurlbut, J. B., & Robert, J. S. (2012) · Journal of Policy Analysis and Management · doi:10.1002/pam.21611 · Cited by 6
Maury, Y., Gauthier, M., Peschanski, M., & Martinat, C. (2011) · médecine/sciences · doi:10.1051/medsci/2011274023 · Cited by 8
“Amyotrophie spinale infantile Diminution de SMN (survival motor neuron) et défaut d’épissage de l’exon 7 Le nombre et la taille des motoneurones diminuent au cours de la culture et de la maturation [19]”
BackgroundMicroRNAs and Induced Pluripotent Stem Cells for Human Disease Mouse Modeling
Underbayev, C., Kasar, S. N., Yuan, Y., & Raveche, E. S. (2012) · BioMed Research International · doi:10.1155/2012/758169 · Cited by 8
Spinal muscular atrophy at the crossroads of basic science and therapy
Sleigh, J. N., Grice, S. J., Davies, K. E., & Talbot, K. (2012) · Neuromuscular Disorders · doi:10.1016/j.nmd.2012.08.008 · Cited by 6
“The first iPSCs derived from somebody with SMA were taken from a three year old Type I patient and his unaffected mother [70].”
BackgroundSpinal Muscular Atrophy Therapeutics Development
Sunshine, S., Jarecki, J., MacKenzie, A., & Chen, K. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803685-3.00016-1 · Cited by 6
Analysis of the mechanism underlying liver diseases using human induced pluripotent stem cells
Kakinuma, S., & Watanabe, M. (2019) · Immunological Medicine · doi:10.1080/25785826.2019.1657254 · Cited by 7
“Differentiation methods of various types of somatic stem cells and their progeny, including neurons [9],”
Genome editing in stem cells for genetic neurodisorders
Dell’Amico, C., Tata, A., Pellegrino, E., Onorati, M., & Conti, L. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.12.006 · Cited by 6
Umek, T., Olsson, T., Gissberg, O., Saher, O., Zaghloul, E. M., Lundin, K. E., Wengel, J., Hanse, E., Zetterberg, H., Vizlin‐Hodzic, D., et al. (2021) · Nucleic Acid Therapeutics · doi:10.1089/nat.2021.0021 · Cited by 7
“This approach has been used to generate in vitro models for several genetic as well as sporadic conditions [26–31].”
Behl, T., Kaur, I., Sehgal, A., Singh, S., Sharma, N., Chigurupati, S., Felemban, S. G., Alsubaiyel, A. M., Iqbal, M. S., Bhatia, S., et al. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10390-4 · Cited by 6
Lv, Y., Qin, Y. F., Wang, J., Tian, G., Wang, W., Cao, C., & Zhang, Y. (2023) · BMC Genomics · doi:10.1186/s12864-023-09285-6 · Cited by 6
Adult-Derived Pluripotent Stem Cells
Faulkner, S. D., Vawda, R., & Fehlings, M. G. (2013) · World Neurosurgery · doi:10.1016/j.wneu.2013.08.004 · Cited by 7
Miranda, C. C., Fernandes, T. G., Diogo, M. M., & Cabral, J. M. S. (2019) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2019_117 · Cited by 8
Progress in understanding epigenetic remodeling during induced pluripotency
Gao, R., Liu, X., & Gao, S. (2015) · 中国科学通报:英文版 · doi:10.1007/s11434-015-0919-4 · Cited by 6
“Patient-specific iPS cells have also been successfully derived by several groups [5–9], which foretells the huge potential of iPS cells”
BackgroundOh, S. K. W., & Choo, A. B. H. (2011) · Elsevier eBooks · doi:10.1016/b978-0-08-088504-9.00038-6 · Cited by 7
Callaway, E. (2011) · Nature · doi:10.1038/469279a · Cited by 6
The state of the art in stem cell biology and regenerative medicine: the end of the beginning
Snyder, E. Y. (2017) · Pediatric Research · doi:10.1038/pr.2017.258 · Cited by 7
Brás, I. C., Xie, Y., & Southwell, A. L. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.17.665403 · Cited by 6
“Neural stem cells (NSCs) were generated from iPSCs lines originally created from human fibroblasts [43, 44].”
Pluripotency genes of mammals: a network at work
Cancedda, R., & Mastrogiacomo, M. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1578499 · Cited by 6
Metadata
- Authors
- Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N.
- Affiliations
- University of Wisconsin–Madison (US)
- University of Missouri (US)
- Corresponding author
- Ebert, Allison D.
- Svendsen, Clive N.
- Venue
- Nature
- Published
- 2008-12-21
- Volume
- 457
- Issue
- 7227
- Pages
- 277-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2659408
- OpenAlex
- W2145492799
- Cited by
- 1,441
- References
- 42
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 28 · 2023: 31 · 2022: 36 · 2021: 33 · 2020: 46 · 2019: 54 · 2018: 53 · 2017: 60 · 2016: 85 · 2015: 109 · 2014: 112 · 2013: 145 · 2012: 199
- FWCI
- 58.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute on Aging (T32AG027566)
- National Institute of General Medical Sciences (T32GM008396)
- National Institute of Neurological Disorders and Stroke (R01 NS41584, P01NS057778, R01NS041584)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD054413)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- spinal muscular atrophy, induced pluripotent stem cells, motor neurons, SMN1, SMN2, dermal fibroblasts, disease modeling, neural progenitor cells, drug screening, inherited neurological diseases, Huntington's disease
- MeSH terms
- Cell Differentiation, Cell Separation, Cells, Cultured, Child, Female, Fibroblasts, Gene Expression Regulation, Humans, Male, Models, Biological, Motor Neurons, Muscular Atrophy, Spinal, Skin, Cell Lineage, Pluripotent Stem Cells, Survival of Motor Neuron 1 Protein, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.